

# ADXS-HER2 Metastatic Solid Tumors

## Phase 1B Monotherapy in Multiple HER2-Expressing Tumors


- Osteosarcoma
- Breast
- Gastric
- Other Cancers

**ADVAXIS**  
IMMUNOTHERAPIES™



### Eligibility

- n≤18 (dose finding); n≤80 (expansion phase in tumor-specific subgroups)
- HER2-positive solid tumor
- Disease progressed or intolerant to standard therapy
- ECOG performance status 0–1
- 3+3 phase 1 design with possible expansion phase in up to 4 different indications



### Primary Endpoints:

- Safety
- RP2D

## 2017 Pediatric Osteosarcoma Study

- Planned with Children’s Oncology Group

**CHILDREN'S  
ONCOLOGY  
GROUP**